These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9614446)

  • 1. Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology Group.
    Kasai T; Ohe Y; Nishio K; Kunitoh H; Tamura T; Sekine I; Kubota K; Yamamoto N; Nakamura Y; Shinkai T; Kodama T; Saijo N
    Jpn J Clin Oncol; 1998 Mar; 28(3):214-21. PubMed ID: 9614446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Prognosis of Patients With Advanced Non-Small-cell Lung Cancer Who Are Ineligible for Clinical Trials.
    Kawachi H; Fujimoto D; Morimoto T; Ito M; Teraoka S; Sato Y; Nagata K; Nakagawa A; Otsuka K; Tomii K
    Clin Lung Cancer; 2018 Sep; 19(5):e721-e734. PubMed ID: 29934133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Problems with registration-directed clinical trials for lung cancer in Japan.
    Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Saijo N; Tamura T
    Tohoku J Exp Med; 2007 Sep; 213(1):17-23. PubMed ID: 17785949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World.
    Karim S; Xu Y; Kong S; Abdel-Rahman O; Quan ML; Cheung WY
    Clin Oncol (R Coll Radiol); 2019 Sep; 31(9):e160-e166. PubMed ID: 31133363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Originality benefit and difficulty of clinical research in the West Japan Lung Cancer Group.
    Kawahara M; Ariyoshi Y; Fukuoka M; Furuse K
    Crit Rev Oncol Hematol; 2000 Oct; 36(1):9-12. PubMed ID: 10996519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generalization and representativeness of phase III immune checkpoint blockade trials in non-small cell lung cancer.
    Yoo SH; Keam B; Kim M; Kim TM; Kim DW; Heo DS
    Thorac Cancer; 2018 Jun; 9(6):736-744. PubMed ID: 29682899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
    Somer RA; Sherman E; Langer CJ
    Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of cancer cooperative groups in Japan.
    Fukuda H
    Jpn J Clin Oncol; 2010 Sep; 40(9):881-90. PubMed ID: 20670961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eligibility of real-world patients with metastatic breast cancer for clinical trials.
    Batra A; Kong S; Cheung WY
    Breast; 2020 Dec; 54():171-178. PubMed ID: 33120082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improving the infrastructure for clinical trials in Japan].
    Nakano S
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):225-30. PubMed ID: 9987523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.
    Statler A; Othus M; Erba HP; Chauncey TR; Radich JP; Coutre S; Advani A; Nand S; Ravandi F; Mukherjee S; Sekeres MA
    Blood; 2018 Jun; 131(25):2782-2788. PubMed ID: 29618479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to reporting guidelines and clinical trial registration policies in oncology journals: a cross-sectional review.
    Wayant C; Moore G; Hoelscher M; Cook C; Vassar M
    BMJ Evid Based Med; 2018 Jun; 23(3):104-110. PubMed ID: 29653939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of staffing and infrastructures of paediatric oncology and haematology centres in Germany].
    Herold R; Reiche R; Creutzig U; Henze G
    Klin Padiatr; 2007; 219(6):380-90. PubMed ID: 18050051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole.
    Cottin V; Arpin D; Lasset C; Cordier JF; Brune J; Chauvin F; Trillet-Lenoir V
    Ann Oncol; 1999 Jul; 10(7):809-15. PubMed ID: 10470428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality assurance in clinical trials.
    Ottevanger PB; Therasse P; van de Velde C; Bernier J; van Krieken H; Grol R; De Mulder P
    Crit Rev Oncol Hematol; 2003 Sep; 47(3):213-35. PubMed ID: 12962897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trends of lung cancer incidence and its prognosis in Osaka, Japan].
    Hanai A; Sobue T; Tsukuma H; Hiyama T; Fujimoto I
    Gan To Kagaku Ryoho; 1994 May; 21(6):727-35. PubMed ID: 8185326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compliance with Good Clinical Practice in oncology registration trials in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Ann Oncol; 2011 Jun; 22(6):1451-1456. PubMed ID: 21119030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Italian cancer figures, report 2012: Cancer in children and adolescents.
    ; ;
    Epidemiol Prev; 2013; 37(1 Suppl 1):1-225. PubMed ID: 23585445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When are clinical trials registered? An analysis of prospective versus retrospective registration.
    Harriman SL; Patel J
    Trials; 2016 Apr; 17():187. PubMed ID: 27079379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.